Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467107 | 0.78 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL31416861 | 0.77 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL14723547 | 0.76 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL11617 | 0.76 | FDPS (0.33) | NPC1 | |
| Ammonia Solution, Strong SCHEMBL27898568 | 0.75 | FDPS (0.32) | — | |
| SCHEMBL3496820 | 0.73 | DGAT1 (0.35) | NPC1RAB9ASMN1; SMN2DGAT1 | |
| SCHEMBL401354 | 0.72 | ALDH1A1 (0.39) | ALDH1A1NPC1KMT2ADGAT1 | |
| SCHEMBL31308722 | 0.72 | DGAT1 (0.35) | NPC1DGAT1 | |
| SCHEMBL20744490 | 0.72 | DGAT1 (0.40) | NPC1SMN1; SMN2DGAT1 | |
| SCHEMBL30789772 | 0.72 | DGAT1 (0.33) | NPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066350-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-02-27 | — | — | US | disclosed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066350-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ATR, WEE1, WEE2 | KDM4E 2259/4885ALDH1A1 2265/4885NPC1 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.